News

The latest from Velocity Clinical Research

Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism

August 18, 2025

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in … Read more

Not All AI Belongs in Clinical Trials. Here’s How We Decide Which Models Do.

August 14, 2025

It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools are too capable, and the commercial advantage too significant, for them not to become … Read more

Velocity Appoints Dr. Sarah Smiley as Chief Physician Officer

August 8, 2025

Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley … Read more

Velocity Appoints Ines Abs as Country Head for Germany, Strengthening European Leadership Amid Market Consolidation

August 1, 2025

Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two … Read more

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

July 17, 2025

Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence (AI) to one of … Read more

Velocity Recognized as a Top Enrolling Site Network in Q1 2025 by AstraZeneca

July 16, 2025

We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio. This recognition is a testament to the dedication of our teams around the world who work … Read more

Douglas K. Logan, MD, and David Ensz, MD, Author Nature Communications Article

July 3, 2025

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that … Read more

An interview with Daniel Williams, DO on Velocity’s PIVOT program and training the next generation of Principal Investigators

July 2, 2025

Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by surprise. “Much of my experience with clinical research centered around reviewing journal articles for … Read more

Could clinical trials be a safe healthcare space for the LGBTQ+ community?

June 30, 2025

By Stephanie Anderson, Chief of Staff Representation in clinical trials is crucial for equitable healthcare. Yet, the nature of clinical trial sites, which have historically been based in municipal centers where patient populations are highest, automatically excludes huge swathes of the population, such as … Read more

Dr. Rosenstock is the Lead Investigator for Lilly’s ACHIEVE-1 Trial for Oral GLP-1, Orforglipron, Results Published in NEJM

June 23, 2025

Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific … Read more

Velocity Joins Advarra’s Council for Responsible Use of AI in Clinical Trials as Founding Member

June 18, 2025

We’re proud to share that Velocity Clinical Research has joined Advarra’s newly launched Council for Responsible Use of AI in Clinical Trials as a founding member—alongside fellow industry leaders from Sanofi and Recursion. This cross-industry initiative will focus on setting standards, defining measurable outcomes, … Read more

BioSpace Article: U.S. Uncertainty Creates Clinical Trial Leadership Opportunity for Europe

June 17, 2025

The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if it acts decisively. In his latest op-ed for BioSpace, Craig Koch examines why this … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.